The global multifocal intraocular lenses (IOLs) market is experiencing steady growth, driven by the rising prevalence of cataracts and presbyopia, an aging global population, and increasing demand for premium vision correction solutions. Advances in lens technology, such as extended depth of focus (EDOF) and trifocal IOLs, are enhancing patient outcomes by reducing dependence on glasses and improving visual clarity across multiple distances. North America and Europe dominate the market due to high adoption rates, technological advancements, and favorable reimbursement policies, while the Asia-Pacific region is witnessing rapid expansion due to increasing healthcare investments and a growing elderly population. Key players such as Zeiss Group, HOYA Medical, Johnson & Johnson Vision Care, Alcon, and Rayner Group are focusing on innovation, product development, and strategic partnerships to expand their market presence.
Global Multifocal IOL Market size was valued at USD 1.25 billion in 2024 and is projected to reach USD 2.05 billion by 2032, with a CAGR of 6.40% during the forecast period of 2025 to 2032.
To know more, visit https://www.databridgemarketresearch.com/reports/global-multifocal-iols-market
Below are the Top Multifocal IOLs Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Zeiss Group
|
Carl Zeiss Meditec AG, a subsidiary of the Zeiss Group, is a leading German medical technology company specializing in ophthalmic devices and solutions. The company offers a range of multifocal IOLs designed to provide patients with clear vision at multiple distances, reducing dependence on corrective eyewear. Their portfolio includes advanced trifocal lenses that cater to near, intermediate, and distance vision needs.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In March 2023, The ZEISS Group design and innovate IOL and OVD Portfolio to address both patient needs and surgeon preferences. Combining innovation and precision, it offers a comprehensive selection of cataract consumables and implants, tailored for monofocal, toric, and refractive cataract surgeries.
|
|
2.
|
HOYA Medical Singapore Pte. Ltd.
|
HOYA Corporation, headquartered in Japan, operates its medical division through subsidiaries like HOYA Medical Singapore Pte. Ltd. The company is renowned for its development and manufacturing of innovative ophthalmic lenses, including multifocal IOLs. HOYA's multifocal IOLs are designed to enhance visual acuity across various distances, utilizing advanced optical designs to improve patient outcomes.
|
|
North America, Asia-Pacific, and Europe
|
In January 2018, HOYA Surgical Optics (HSO) today officially launched its new global research and development (R&D) facility in Singapore to develop new breakthrough technologies in intraocular lens (IOL), a lens that is implanted as part of the treatment for cataract.
|
|
3.
|
Johnson & Johnson Vision Care, Inc.
|
Johnson & Johnson Vision Care, a division of Johnson & Johnson MedTech, is a prominent player in the ophthalmic industry. The company offers a comprehensive range of vision care products, including multifocal IOLs. Their TECNIS line of multifocal IOLs is engineered to provide high-quality vision across different distances, aiming to reduce the need for glasses post-surgery.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In February 2020, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. stated the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking sanction of DARZALEX in combination with Kyprolis and dexamethasone for relapsed/refractory multiple myeloma. If approved this will increase the product portfolio and also revenue generation of the company.
|
|
4.
|
Alcon Inc.
|
Alcon Inc., based in Switzerland, is a global leader in eye care products. The company's multifocal IOL offerings are designed to address presbyopia and cataract-related vision issues, providing patients with improved visual performance at various distances. Alcon's AcrySof IQ Vivity IOL, for instance, utilizes innovative technology to deliver an extended range of vision.
|
|
North America, Middle East and Africa, Asia-Pacific, and Europe
|
In April 2024, Alcon, the global leader in eye care dedicated to helping people see brilliantly, showcased approximately 100 company-supported and investigator-led data presentations demonstrating its latest innovative efforts aimed at optimizing patient outcomes at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8 in Boston. In addition, the company hosts multiple peer-to-peer symposia and in-booth demonstrations of its industry-leading implantables and devices, including the Clareon intraocular lens (IOL) portfolio, cloud-based SMARTCataract surgical planner, Hydrus Microstent and more.
|
|
5.
|
Rayner Group
|
Rayner Group, headquartered in the U.K., has a long-standing history in the development of intraocular lenses. The company's multifocal IOLs are crafted to offer patients enhanced visual clarity at multiple focal points, aiming to improve quality of life by reducing dependence on spectacles. Rayner continues to innovate in the field of ophthalmology, focusing on patient-centric solutions.
|
|
South America, Africa, Asia-Pacific
|
In April 2024, Rayner, a global manufacturer of products for cataract surgery based in Worthing, UK, proudly announces delivery of its 5 millionth RayOne lens (and 11 millionth lens made from RayAcryl Rayner’s proprietary hydrophilic acrylic material), marking an important milestone in units sold globally.
|
Conclusion
The global multifocal intraocular lenses (IOLs) market is poised for continued growth, driven by increasing demand for advanced vision correction solutions, technological innovations, and a growing aging population affected by cataracts and presbyopia. Market leaders such as Zeiss Group, HOYA Medical, Johnson & Johnson Vision Care, Alcon, and Rayner Group are investing in research and development to enhance lens performance and expand their global reach. While North America and Europe remain dominant due to high adoption rates and supportive healthcare infrastructure, the Asia-Pacific region presents significant growth opportunities. Challenges such as high costs and surgical risks persist, but ongoing advancements in lens technology and improved patient awareness are expected to drive greater acceptance. As the preference for premium, spectacle-free vision continues to rise, the multifocal IOLs market is set to expand, offering improved visual outcomes and better quality of life for patients worldwide.
